Pelage Pharma is pioneering a novel approach to hair loss treatment that is fundamentally rooted in stem cell biology. The company has developed a small molecule drug platform that directly targets hair follicle stem cells (HFSCs) to stimulate hair growth. This innovative technology is based on groundbreaking research from UCLA scientists, which identified a unique metabolic switch in HFSCs that can be activated to restore their regenerative capacity. By focusing on the intrinsic metabolic properties of these stem cells, Pelage's treatment aims to induce robust hair growth across various demographics, including all genders and hair types, without the need for invasive procedures or systemic oral medications.

The Pelage solution addresses the limitations of existing hair loss treatments, which often target external factors and have varying degrees of efficacy. Current therapies, such as anti-androgen drugs and minoxidil, may not be suitable for all patients and can involve invasive procedures. In contrast, Pelage's approach is non-invasive and clinically tested, aiming to reactivate dormant HFSCs that may be "stuck" in a dormant phase due to factors like age, stress, or hormonal changes. The company is currently conducting a Phase 2a clinical trial to evaluate the safety and efficacy of its lead product, PP405, which has shown promising results in preliminary studies by significantly activating stem cell proliferation in hair follicles.

United States

Pelage is a clinical-stage regenerative medicine company developing novel treatments for hair loss, including androgenetic alopecia. Based on discoveries in stem cell biology made by Pelage's scientific co-founders, the company's novel approach is designed to reactivate dormant hair follicle stem cells and restore the body's ability to grow hair naturally.

Pelage Pharma

Company Details